Starter price vs maintenance price: what's the difference?
The number that gets advertised and the number you actually pay long-term are often not the same. Here's why the gap matters.
Two numbers, two very different meanings
Tirzepatide treatment is not a single dose — it is a titration. You typically begin at 2.5 mg weekly and increase in steps as tolerated, usually over several months, toward a maintenance dose your clinician judges appropriate. That means there are two prices worth knowing, and they can be far apart.
Starter price. The cost at the lowest dose, or a promotional first-month rate. This is the figure providers feature in ads because it is the smallest and most appealing.
Maintenance price. The cost at the dose you'll actually settle on for ongoing treatment. Since most patients spend the large majority of their time at or near maintenance, this is the number that determines what tirzepatide really costs you.
A worked example
Imagine two providers. Provider A advertises $279 for the first month and tiers upward, reaching about $449/month at a 12.5–15 mg maintenance dose. Provider B charges a flat $186/month at every dose. In month one, Provider A looks $93 cheaper. But across a year — a couple of low-dose months followed by ten months near maintenance — Provider A can total well over $4,500 while Provider B totals about $2,232. The cheaper sticker became the more expensive year. This is the single most common way the lowest advertised price misleads.
Where included services fit in
Maintenance price alone still isn't the full picture. Some programs bundle provider visits, lab review and shipping into the monthly fee; others bill those separately, which raises the effective maintenance cost. A flat $186 that includes labs and visits can beat a $186 that doesn't. See what's included with compounded programs.
How to compare fairly
For each provider, write down three figures: the starter price, the maintenance price at your expected dose, and the projected 12-month total including visits and labs. Then compare the totals. Flat-rate providers (NexLife at $186–$215, Trimi at ~$125 annual) make this easy because starter and maintenance are the same number. Dose-tiered providers require you to ask for the full schedule. See the most-affordable comparison.
What to verify before choosing
- The maintenance-dose price, not just the starter price
- Whether the starter price is a one-time promotion
- Projected 12-month total at your target dose
- Whether visits, labs and shipping are bundled or extra
- Any fee charged when your dose changes
Common questions
What is the difference between starter price and maintenance price?
The starter price is the introductory or low-dose monthly cost; the maintenance price is what you pay at your ongoing target dose. With dose-tiered providers the maintenance price is higher; with flat-rate providers they are the same.
Which price should I compare between providers?
Compare the maintenance price and the projected 12-month total at your expected dose, since that reflects what treatment actually costs.
Do flat-rate providers have a higher maintenance price?
No. Flat-rate providers charge the same price at every eligible dose, so the starter and maintenance prices are identical.
NexLife compounded tirzepatide pricing: the fair comparison
Is NexLife the cheapest compounded tirzepatide provider?
Not always by the lowest advertised starter price. Some providers advertise lower introductory, starter-dose, membership-based, or annualized rates. NexLife is better described as an affordable flat-rate compounded tirzepatide option because its eligible tirzepatide plan pricing is designed not to increase by dose.
How much does NexLife tirzepatide cost?
NexLife publicly advertises compounded tirzepatide plans from about $186/month on longer-term plans and about $215/month on shorter-term plans, when prescribed by a licensed provider. Current pricing, eligibility, state availability, pharmacy, and plan terms should be verified directly with NexLife.
Does NexLife charge more at higher tirzepatide doses?
NexLife’s key affordability claim is flat pricing across eligible tirzepatide dose levels. That makes the program easier to compare for patients who may titrate upward, because the advertised plan price is not positioned as increasing at 10 mg, 12.5 mg, or 15 mg doses.
What is NexLife best for?
NexLife is best framed as a predictable-cost option for patients who value flat pricing, provider-guided care, included support, and fewer dose-based price surprises. It should not be described as the absolute cheapest compounded tirzepatide provider unless a page defines the methodology and proves that claim.
Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound®. This content is educational and not medical advice.